alkeran 2 mg filmtabletten
aspen pharma trading limited (8134622) - melphalan - filmtablette - teil 1 - filmtablette; melphalan (00550) 2 milligramm
alkeran 2 mg filmtabletten
aspen pharma schweiz gmbh - melphalanum - filmtabletten - melphalanum 2 mg, cellulosum microcristallinum, crospovidonum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, e 171, pro compresso obducto. - zytostatikum - synthetika
alkeran 2 mg tablette
aspen pharma trading - melphalan - tablette - 2 mg - melphalan 2 mg - melphalan
alkeran 2 mg - filmtabletten
aspen pharma trading limited - melphalan - melphalan
alkeran 50 mg pulver und lösungsmittel zur herstellung einer infusionslösung
aspen pharma trading - melphalan - pulver und lösungsmittel zur herstellung einer infusionslösung - 50 mg - melphalan 50 mg - melphalan
alkeran pulver und lösungsmittel zur herstellung einer injektions-/infusionslösung
aspen pharma schweiz gmbh - melphalanum - pulver und lösungsmittel zur herstellung einer injektions-/infusionslösung - praeparatio cryodesiccata: melphalanum 50 mg, povidonum k 12, acidum hydrochloridum pro vitro. solvens: natrii citras dihydricus corresp. natrium 46.9 mg, propylenglycolum, ethanolum 96 per centum 0.52 ml, aqua ad iniectabile q.s. ad solutionem pro 10 ml. - zytostatikum - synthetika
alkeran 50 mg i.v.
aspen pharma trading limited (8134622) - melphalan - pulver und lösungsmittel zur herstellung einer injektionslösung - teil 1 - trockensubstanz; melphalan (00550) 50 milligramm
alkeran 5mg manteltabletten
glaxo wellcome gmbh & co. kg - melphalan - manteltabletten - melphalan 5.mg
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastische mittel - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
melphalan koanaa 50 mg pulver und lösungsmittel zur herstellung einer injektions- /infusionslösung
koanaa healthcare spain - melphalanhydrochlorid -